Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer

Osimertinib is a standard first-line treatment for patients with metastatic non-small cell lung cancer harboring an epidermal growth factor receptor exon 19 deletion or exon 21 L858R mutation. Although osimertinib can provide effective disease control, most patients eventually experience disease progression, and the primary lung tumor may remain an important site of treatment resistance. This multicenter, randomized, open-label phase III trial will evaluate whether surgical removal of the primary lung tumor, in addition to continued osimertinib treatment, prolongs progression-free survival in

Trial Details

NCT ID

NCT07738172

Phase

PHASE3

Sponsor

National Taiwan University Hospital

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

• Primary Tumor Resection
• Osimertinib

Locations (sample)

• Taipei, Taipei City, Taiwan|25.05306,121.52639

Key Eligibility Criteria

• Histologically or cytologically confirmed NSCLC.
• Age ≥18 years.
• AJCC 8th edition stage IV NSCLC.
• EGFR sensitizing mutation limited to exon 19 deletion or exon 21 L858R.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →